Study objectives To provide a systematic overview of the literature investigating patient and
tumor factors that are predictive of survival for patients with non-small cell lung cancer …

Differential diagnosis of suspicious lung masses is essential for the selection of the
appropriate therapy strategy. While non-small cell lung cancer (NSCLC) in early stages and …

The purpose of this study was to determine the prognostic significance of a high
pretreatment serum CYFRA 21-1 level (a cytokeratin 19 fragment) adjusted for the effects of …

Tumor marker serum levels were prospectively studied in 289 patients with suspected, but
unconfirmed, lung cancer and in 513 patients with lung cancer [417 non-small cell lung …

Background: CYFRA 21-1, a serum cytokeratin 19 fragment, and neuron specific enolase
(NSE), the γ-subunit of enolase, are putative markers of lung cancer. Their clinical …

Objective: To assess the value of Cyfra 21-1, carcino-embryonic antigen (CEA) and neuron-
specific enolase (NSE) combined, all three together as prognostic factors in advanced stage …

Currently, no further therapy in addition to surgery is recommended in completely resected
NSCLC stage I patients. However, the 5-year survival rate at this stage has been reported to …

Background Microbes colonizing lower airways can regulate the host immune profile and
consequently participate in lung disease. Increasing evidence indicate that individual …

Lung tumor markers fall into several categories including oncofetal proteins, structural
proteins and their fragments, enzymes, membrane antigens, peptide and non-peptide …

目的: 探讨血清肿瘤标志物癌胚抗原(carcinoembryonic antigen, CEA), 癌抗原19-9
(carbohydrate antigen, CA19-9) 和细胞角蛋白19 片段(cytokeratin-19 fragments, CK19) …